Innovation Sphere

Projects Sharing Researchers

Communicate

Details

Project TitleRegulation Of Tumor-Associated T-Cells
Track Code16028
Short Description

Identification of a novel cell type that appears to play a role in the t cell therapy of cancer


 
Abstract

The invention relates to the use of ex-vivo expanded tumor-infiltrating lymphocytes (TILs) as a potential treatment modality for cancer. It further details compositions of these TILs between patients and how this relates to prognosis and methods for improving TIL expansion and function for the treatment of cancer.

We have identified a novel regulatory cell type, innate lymphoid cells (ILC), that appear to impact TILs. Specifically, administering to the patient a therapeutically effective amount of a compound that decreases the suppressive effect of ILCs can have an impact on tumor infiltrating lymphocyte (TIL) propagation, expansion or function.


 
 
Tagstherapeutics, cancer, immune-oncology, cell therapy, regenerative medicine, stem cell, platform, Tumor Infiltrating Lymphocytes, REGULATION OF TUMOR-ASSOCIATED T-CELLS
 
Posted DateJun 8, 2017 5:34 PM

Potential Applications

  • Cancer treatment
  • Regenerative medicine
  • Immunotherapy

Principal Investigator

Drs. Sarah Crome and Pamela Ohashi, University Health Network

Patent Status

Provisional application has been filed US62/375,970

Partnering Opportunity

Available for licensing

Publications

Nat Med. 2017 Mar;23 (3):368-375. A distinct innate lymphoid cell population regulates tumor-associated T cells

For Further Information, Please Contact:

Rahbar Rahimpour, PhD, MBA | Licensing and Commercialization Professional | Technology Development and Commercialization | University Health Network | +1 (416) 581-7728 | rahbar.rahimpour@uhnresearch.ca